AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors (AMPARs) mediate fast excitatory neurotransmission in the brain. AMPARs form by homo- or heteromeric assembly of subunits encoded by the GRIA1-GRIA4 genes, of which only GRIA3 is X-chromosomal. Increasing numbers of GRIA3 missense variants are reported in patients with neurodevelopmental disorders (NDD), but only a few have been examined functionally. Here, we evaluated the impact on AMPAR function of one frameshift and 43 rare missense GRIA3 variants identified in patients with NDD by electrophysiological assays. Thirty-one variants alter receptor function and show loss-of-function (LoF) or gain-of-function (GoF) properties, whereas 13 appeared neutral. We collected detailed clinical data from 25 patients (from 23 families) harbouring 17 of these variants. All patients had global developmental impairment, mostly moderate (9/25) or severe (12/25). Twelve patients had seizures, including focal motor (6/12), unknown onset motor (4/12), focal impaired awareness (1/12), (atypical) absence (2/12), myoclonic (5/12), and generalized tonic-clonic (1/12) or atonic (1/12) seizures. The epilepsy syndrome was classified as developmental and epileptic encephalopathy in eight patients, developmental encephalopathy without seizures in 13 patients, and intellectual disability with epilepsy in four patients. Limb muscular hypotonia was reported in 13/25, and hypertonia in 10/25. Movement disorders were reported in 14/25, with hyperekplexia or non-epileptic erratic myoclonus being the most prevalent feature (8/25). Correlating receptor functional phenotype with clinical features revealed clinical features for GRIA3-associated NDDs and distinct NDD phenotypes for LoF and GoF variants. GoF variants were associated with more severe outcomes: patients were younger at the time of seizure onset (median age one month), hypertonic, and more often had movement disorders, including hyperekplexia. Patients with LoF variants were older at the time of seizure onset (median age 16 months), hypotonic, and had sleeping disturbances. LoF and GoF variants were disease-causing in both sexes but affected males often carried de novo or hemizygous LoF variants inherited from healthy mothers, whereas all but one affected females had de novo heterozygous GoF variants.

Gain-of-function and loss-of-function variants in GRIA3 lead to distinct neurodevelopmental phenotypes / B. Rinaldi, A. Bayat, L.G. Zachariassen, J. Sun, Y. Ge, D. Zhao, K. Bonde, L.H. Madsen, I.A.A. Awad, D. Bagiran, A. Sbeih, S.M. Shah, S. El-Sayed, S.M. Lyngby, M.G. Pedersen, C. Stenum-Berg, L.C. Walker, I. Krey, A. Delahaye-Duriez, L.T. Emrick, K. Sully, C.N. Murali, L.C. Burrage, J.A. Plaud Gonzalez, M. Parnes, J. Friedman, B. Isidor, J. Lefranc, S. Redon, D. Heron, C. Mignot, B. Keren, M. Fradin, C. Dubourg, S. Mercier, T. Besnard, B. Cogne, W. Deb, C. Rivier, D. Milani, M.F. Bedeschi, C. Di Napoli, F. Grilli, P. Marchisio, S. Koudijs, D. Veenma, E. Argilli, S.A. Lynch, P.Y.B. Au, F.E. Ayala Valenzuela, C. Brown, D. Masser-Frye, M. Jones, L. Patron Romero, W.L. Li, E. Thorpe, L. Hecher, J. Johannsen, J. Denecke, V. Mcniven, A. Szuto, E. Wakeling, V. Cruz, V. Sency, H. Wang, J. Piard, F. Kortüm, T. Herget, T. Bierhals, A. Condell, B.B. Zeev, S. Kaur, J. Christodoulou, A. Piton, C. Zweier, C. Kraus, A. Micalizzi, M. Trivisano, N. Specchio, G. Lesca, R.S. Møller, Z. Tümer, M. Musgaard, B. Gerard, J.R. Lemke, Y.S. Shi, A.S. Kristensen. - In: BRAIN. - ISSN 0006-8950. - (2023). [Epub ahead of print] [10.1093/brain/awad403]

Gain-of-function and loss-of-function variants in GRIA3 lead to distinct neurodevelopmental phenotypes

B. Rinaldi;D. Milani;F. Grilli;P. Marchisio;
2023

Abstract

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors (AMPARs) mediate fast excitatory neurotransmission in the brain. AMPARs form by homo- or heteromeric assembly of subunits encoded by the GRIA1-GRIA4 genes, of which only GRIA3 is X-chromosomal. Increasing numbers of GRIA3 missense variants are reported in patients with neurodevelopmental disorders (NDD), but only a few have been examined functionally. Here, we evaluated the impact on AMPAR function of one frameshift and 43 rare missense GRIA3 variants identified in patients with NDD by electrophysiological assays. Thirty-one variants alter receptor function and show loss-of-function (LoF) or gain-of-function (GoF) properties, whereas 13 appeared neutral. We collected detailed clinical data from 25 patients (from 23 families) harbouring 17 of these variants. All patients had global developmental impairment, mostly moderate (9/25) or severe (12/25). Twelve patients had seizures, including focal motor (6/12), unknown onset motor (4/12), focal impaired awareness (1/12), (atypical) absence (2/12), myoclonic (5/12), and generalized tonic-clonic (1/12) or atonic (1/12) seizures. The epilepsy syndrome was classified as developmental and epileptic encephalopathy in eight patients, developmental encephalopathy without seizures in 13 patients, and intellectual disability with epilepsy in four patients. Limb muscular hypotonia was reported in 13/25, and hypertonia in 10/25. Movement disorders were reported in 14/25, with hyperekplexia or non-epileptic erratic myoclonus being the most prevalent feature (8/25). Correlating receptor functional phenotype with clinical features revealed clinical features for GRIA3-associated NDDs and distinct NDD phenotypes for LoF and GoF variants. GoF variants were associated with more severe outcomes: patients were younger at the time of seizure onset (median age one month), hypertonic, and more often had movement disorders, including hyperekplexia. Patients with LoF variants were older at the time of seizure onset (median age 16 months), hypotonic, and had sleeping disturbances. LoF and GoF variants were disease-causing in both sexes but affected males often carried de novo or hemizygous LoF variants inherited from healthy mothers, whereas all but one affected females had de novo heterozygous GoF variants.
AMPA receptor; GRIA; GRIA3; clinical biomarker; genotype-phenotype
Settore MED/38 - Pediatria Generale e Specialistica
2023
1-dic-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
awad403.pdf

embargo fino al 01/12/2024

Descrizione: Journal Article - Accepted Manuscript
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 3.14 MB
Formato Adobe PDF
3.14 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1022895
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact